AngioDynamics (ANGO) 8-K Regulation FD Disclosure

Exhibit 99.1

 J.P. Morgan  Healthcare Conference January 11, 2024  Jim Clemmer, President & CEO 

 A medical technology platform company focused on a select group of large, high growth markets where meaningful treatment gaps exist in current standard of care.  We are transforming our portfolio to be a company focused on investing our resources on innovative technologies backed by science and clinical data. Our technologies positively impact treatment options and patients' quality of life.  AngioDynamics 

 AngioDynamics  Cardiovascular disease and cancer have the highest morbidity and mortality worldwide  Global Cardiovascular Disease Burden1  523M diagnosed in 2020  ~19 million deaths  Cardiovascular Disease causes 1 in 3 deaths globally  Global Cancer Burden2  Cancer causes 1 in 6 deaths globally  19.3M diagnosed in 2020  ~10 million deaths  3  https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-GIobal-Burden-of-Disease.pdf; https://www.cdc.gov/pcd/issues/2022/22_0347.htm  https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660#:~:text=Worldwide%2C%20an%20estimated%2019.3%20million,skin%20cancer)%20occurred%20in%202020. 

 MedTech Markets  4  Targeted segments have attractive underpenetrated addressable markets  Cardiac Thrombus & Emboli  $825M TAM  Pulmonary Embolism  $2.9B TAM  Prostate Cancer  $2B TAM  Deep Vein Thrombosis  $3B TAM  Peripheral Arterial Disease  $1.1B TAM  *AlphaVac PE, Auryon Venous Thrombectomy/DVT, AngioVac Left Heart and Infective Endocarditis are not cleared by the US Food and Drug Administration (FDA) for these indications In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue  The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition. 

 5  AngioDynamics  Investments in our Med Tech platforms are funded by operating cash flows from our Med Device portfolio  Med Tech: Invest for Growth  Disease State  Latest Investment Updates  Peripheral Arterial Disease  Radial length catheter launch Jan 2024  Pathfinder 12 month & 24 month publications Feb & July 2024  Below the knee study publication March 2024  CE Mark expected May 2024  6 additional new product extensions/upgrades scheduled throughout 2024  Coronary Atherectomy pre-submission (PMA) & pilot trial planned to begin in 2024  Venous Thromboembolism  APEX complete, PE indication expected by June 2024  CE Mark for PE expected by June 2024  2 additional new product extensions/upgrades scheduled throughout 2024  IDE clinical trial for Auryon DVT to begin in late 2024  Cardiac Thrombus & Emboli  Begin study for Infective Endocarditis indication in 2024  Prostate  PRESERVE Study enrolled, expected Prostate indication by December 2024  Med Device: Maintain Positioning  PICCs, Midlines &  Accessories  Microwave &  Radiofrequency Ablation  Diagnostic Catheters, Guidewires & Kits  Implantable Ports  Endovenous Laser Treatment  Radiation Treatment Stabilization Balloons  *AlphaVac PE, Auryon Venous Thrombectomy/DVT, Auryon Coronary Atherectomy, AngioVac Left Heart and Infective Endocarditis are not cleared by the US Food and Drug Administration (FDA) for these indications In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue.  The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.  The planned portfolio additions and new indications are based on management estimates and industry sources as of July 2022 and are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. 

 PAD  As of November 2023, the Auryon Atherectomy System has treated over 50,000 patients and reached $100M cumulative sales since its September 2020 launch  6  T H E M A R K E T  O U R S O L U T I O N  Peripheral Atherectomy  Protective of vessel wall c-e  Targeted biological reactions to address risk of perforations  Built-in aspiration to address risk of embolization†  †Built-in aspiration available with the 2.0-and 2.35-mm catheters.  W H Y I T M A T T E R S  Treat all levels of calcification a-c  Indicated for in-stent restenosis*  Treats above and below the knee (inc. below the ankle)  *2.0mm and 2.35mm catheters are indicated for ISR.  Designed for hospital and lab a-c, f  Portable, 110V outlet, low noise, touch screen  Debulk in fewer passes  2022 TAM  $1.1B  a-f See reference page  “We’ve always known that Auryon’s technology is one-of-a-kind and unmatched. With the new [hydrophilic  coating], we should be able to prove this – case after case after case”  – Dr. Curtis Anderson, Vascular & Interventional Radiologist  Europe APAC US  $760M  $210M  $100M  Source: Management estimate & industry sources as of July 2022. 

 Thrombus Management  Our differentiated technology platforms offer potential treatment solutions across multiple disease states  T H E M A R K E T O U R S O L U T I O N  W H Y I T M A T T E R S  Only solution on the market with continuous aspiration and simultaneous reinfusion of filtered blood  Aspirates large clot burden  Controlled aspiration  Aspirates large clot burden  APEX-AV study for PE  Right Heart and Left Heart* removal of cardiac thrombus  Large Vessel Venous Thrombectomy/DVT  Pulmonary Embolism*  Small Vessel Venous Thrombectomy/DVT*  7  2022 TAM  $6.7B  M  $3.9  $  1B  $210M  $1B  Auryon’s low profile + laser + aspiration, make it a compelling and simple technology to effectively ablate & remove thrombus with the legs  VTE  PE  Pulmonary Embolism  DVT  Deep Vein Thrombosis  Cardiac  TVIE  Tricuspid Valve Infective Endocarditis  LV  Lead Vegetation  RA  Right Atrial Thrombus  +  Europe APAC US  Europe US  Cardiac  $3.9B  $1B  VTE  $1B  $535M  $290M  Source: Management estimate & industry sources as of July 2022.  *AlphaVac PE, Auryon Venous Thrombectomy/DVT, and AngioVac Left Heart and Infective Endocarditis are not cleared by the US FDA for these indications. 

 Thrombus Management  All-purpose technology platforms targeted at peripheral and cardiovascular thrombolytic events, including small and large vessels  POWERFUL  355 nm laser is designed to deliver an optimized wavelength, pulse width, and amplitude to restore flow in occluded vesselsc, d, g  Small Vessel  The AngioVac System allows for the continuous aspiration of embolic material such as thrombi and emboli from the venous system while simultaneously reinfusing the patient’s own filtered blood to limit procedural blood loss  MULTIPLE TIP ANGLES  200, 850, 1800  PROPRIETARY FUNNEL DESIGN  Allows for Significant Clot Removal  RADIOPAQUE MARKERS  Better Tip Visibility  LARGE END HOLE ASPIRATION  42FR & 30FR Opening  The AlphaVac System allows for the controlled aspiration of embolic material such as thrombi and emboli from the venous system  Large Vessel  PRECISE  Protective of vessel wallc-e  ADAPTABLE  Potential to treat all types of small vessel DVT*  c-g See reference page  *Auryon Venous Thrombectomy/DVT is not cleared by the US FDA for this indication. 

 NanoKnife Prostate Initiative*  Over 505,000 men with prostate cancer could be treated with this technology  9  USA EMEA APAC LAM CAN  *IDE Study in progress; enrollment completed  In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue.  The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.  Market Source: Management estimate & industry sources as of July 2022.  Focal Therapy  O U R S O L U T I O N  W H Y I T M A T T E R S  T H E M A R K E T  2023 Global TAM  $2B  Targeted: Short electric pulses destroy cells without relying on extreme heat or cold and spare vital structures within the ablation zone  Quality of Life: Better preserves urinary control and erectile function  Versatile: Can be used in all segments of the  prostate for primary and recurrent disease  Fast: Minimally invasive treatment that is delivered in a single session  Preserves future treatment options  $702M  $728M  $521M  $30M  $60M 

 International Expansion Plan  Expanding our business reach in targeted regions, markets & countries  10  Aligning our Go-to-Market strategy to the different regions, markets & countries, utilizing new partnerships where appropriate to maximize growth  Preparing for CE Mark and other selected international launches of both the Auryon System and the AlphaVac F1885 System  Auryon CE Mark expected 1H of calendar 2024  AlphaVac F1885 System CE Mark expected 1H of calendar 2024  Continue to increase our global presence through our series of life symposiums which has attracted interest from global key opinion leaders who are gaining more access to our technologies 

 IDE  Clinical Studies and Pathway Expansion  Corporate Developments – Q2 and YTD FY24  Initiated restructuring of manufacturing footprint to a fully outsourced model  Continued portfolio optimization initiatives  Full-year adjusted EPS profitability expected in FY27 Cumulative Auryon sales of over $100.0 million  achieved in November  Q2  Highlights and Operational Developments  PRESERVE study for the treatment of prostate cancer with NanoKnife completed enrollment in July 2023  APEX AV study for the treatment of pulmonary embolism with AlphaVac F1885 System  Completed enrollment in December 2023  Submission to the FDA planned in early calendar 2024  Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife  NanoKnife disposables down 3.6% YOY  Q2 FY24  Revenue  $79.1 mil  Pro Forma Revenue Growth*  2.7%  Med Tech up 3.5%  Med Device up 2.3%*  $11.4 million in Auryon sales; growth of 12.9% YOY  Mechanical Thrombectomy  down 4.7% YOY  $1.9 million in AlphaVac sales AngioVac sales declined 10.8% YOY  * On a pro forma basis, excluding the sale of Dialysis and BioSentry  11 AngioDynamics Second Quarter FY2024 Earnings  12.9% YOY growth in  NanoKnife disposables  YTD FY24  Pro Forma Revenue*  $157.1 mil  Pro Forma Revenue Growth*  4.2%  Med Tech up 8.3%  Med Device up 2.3%*  $22.5 million in Auryon sales; growth of 18.9% YOY  Mechanical Thrombectomy  down 5.3% YOY  $3.7 million in AlphaVac sales AngioVac sales declined 9.2% YOY 

 FY24 Revised Guidance  * FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of $0.43.  12 AngioDynamics Second Quarter FY2024 Earnings  Guidance*  Revised Guidance*  Revenue  $328 - $333 million  $320 - $325 million  Gross Margin  Med Tech Med Device  50.0% - 52.0%  63.0% – 65.0%  43.0% - 45.0%  49.0% - 51.0%  61.0% – 63.0%  43.0% - 45.0%  Adjusted EPS  ($0.28) – ($0.34)  ($0.35) – ($0.42) 

 J.P. Morgan  Healthcare Conference January 11, 2024  Jim Clemmer, President & CEO 

 Auryon References  Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8.  Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser™, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Cardiovas Revasc Med. 2020;21(1):86-92.  Auryon. Instructions for use. AngioDynamics; 2019.  Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary  report. Lasers Surg Med. 2016;48(3):281-287.  Herzog A, Steinberg I, Gaisenberg E, Nomberg R, Ishaaya AA. A route to laser angioplasty in the presence of fluoroscopy contrast media, using a nanosecond-pulsed 355- nm laser. IEEE J Sel Top Quantum Electron. 2016;22(3):342-347.  Kuczmik W, Kruszyna L, Stanisic MG, Dzieciuchowicz L, Ziaja K, Zelawski W, et al. Laser atherectomy using the novel B-Laser™ catheter, for the treatment of femoropopliteal lesions: twelve-month results from the EX-PAD-01 study. Not yet published.  Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103(2):577-644.  14